Neothermia

Contact:
Neothermia Corporation
Thomas M. Tully, President & CEO
508-655-7820

Rx Communications Group
Paula Schwartz (investors) 917-322-2216
Tony H. Loke (media) 917-322-2164

NEOTHERMIA CORPORATION INTRODUCES TWO NEW SIZES OF EN-BLOC® BIOPSY PROBES FOR MORE FLEXIBILITY IN THE DIAGNOSIS OF BREAST CANCER

NATICK, MA, November 30, 2004 – Neothermia Corporation, an emerging leader in the development and marketing of minimally invasive systems for the diagnosis of cancer, announced today that it has added 12mm and 20mm diameter en-bloc® biopsy probes to its offering of breast biopsy devices. The Company currently offers biopsy probes in 10mm and 15mm diameter.

"Clinical data, including the results of a multi-center trial conducted by 14 physicians at 10 U.S. centers presented today at the 2004 Radiological Society of North America (RSNA) meeting (Abstract 4405243), are demonstrating the important diagnostic outcome benefits of the en-bloc®. Of note, the data indicate that the en-bloc® biopsy procedure significantly improves diagnostic accuracy compared to the standard core biopsy technique," said Thomas Tully, President and Chief Executive Officer of Neothermia.

Mr. Tully continued, "By offering additional probe sizes, Neothermia is giving physicians more flexibility in their diagnostic choice. For example, with the new, 12mm probe, physicians can now retrieve almost 60% more volume than the 10mm probe -- providing for increased diagnostic sampling in women with smaller breasts. By the same token, the 20mm en-bloc® probe allows the removal of more than 3g of tissue from the region of the suspicious lesion, giving physicians more flexibility in biopsying larger lesions, such as fibroadenomas."

Management went on to explain that since the en-bloc® procedure produces a large, intact specimen from the region of interest, it is less prone to sampling error, and increases the opportunity for diagnostic accuracy compared to percutaneous core biopsy. Clinical data suggest that many women may have more definitive diagnostic results in their breast biopsy procedures with the en-bloc® and may be spared follow-up surgeries to confirm the benign nature of more complex breast lesions.

Other aspects of the en-bloc® procedure, such as procedure time, cosmetic outcome, patient comfort, etc., are comparable to percutaneous core biopsy.

Neothermia

About the en-bloc® System

The en-bloc® procedure is a vacuum-assisted, image-guided (by ultrasound or stereotactic X-ray) procedure in which a slender probe is inserted through a small incision to remove a small lump of suspicious tissue for pathological analysis. The procedure is performed under local anesthesia and the incision is closed with a steri-strip (bandage).

About Neothermia Corporation

Founded in 1998, and based in Natick, Massachusetts, Neothermia is a privately held company focused on the design, development and marketing of innovative, minimally invasive systems for the volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets. The Company's lead product, the en-bloc® biopsy system, received approval from the Food and Drug Administration in June 2001. Initial products are targeted at breast biopsy and tumor excision.

For more information on Neothermia, please visit the Company's website at www.neothermia.com.

# # #